Amy D Harper, MD
Disclosures: Membership on Advisory Committees or Review Panels, Board Membership, etc.-NS Pharma Advisory Board (Relationship has ended)|Speakers Bureau-Sarepta|Grant or research support-Italafarmaco|Grant or research support-Novartis|Grant or research support-Astellas|Grant or research support-Reveragen|Grant or research support-NIH|Grant or research support-CDC|Grant or research support-AMO|Grant or research support-Avidity Bioscience|Grant or research support-AMO|Grant or research support-Vertex Pharm|Grant or research support-MLBiolutions|Grant or research support-Fulcrum Therapeutics - 02/17/2022

Amy Harper, MD, CINRG Bio


Dr. Harper is an Associate Professor in the Department of Neurology, Division of Child Neurology at Virginia Commonwealth University Health System where she is the Directory of the Children’s Hospital of Richmond Neuromuscular Clinics.


In 1998, she received her MD and entered pediatric residency. Following residency, Dr. Harper completed fellowships (OHSU) in neurodevelopmental disabilities/child neurology and neuromuscular medicine. She was the first neurodevelopmental disabilities training graduate nationwide. Her board certifications have included Pediatrics, Child Neurology and Neuromuscular Medicine.


In 2016, she joined the faculty of the Children’s Hospital of Richmond (CHOR)/VCU Health where she is the Shirley Van Epps Waple ProfessorClinically, her primary Her primary clinical leadership role is serving as Director of the CHOR Neuromuscular program which includes directorship of CHOR’s MDA, Duchenne Certified, and SMA Network Care Centers. Formerly, she was the founder, co-founder and/or director for multidisciplinary High Risk Neonatal, Cerebral Palsy, and Pediatric MDA clinics.


Dr. Harper’s contributions and expertise have been recognized on several levels.  She was voted by her peers as “Top Doc” in Pediatric Neurology 76 times in 2 (2 states, cities (highest votes 2020).  Neurology residents voted her “Best Teacher in Pediatric Neurology” in 2017.    She has been recognized by the MDA, PPMD, Cure SMA, and the NC Epilepsy Foundation for her clinical care. Nationally, she served previously as an Executive Committee member s as an Executive Committee member for the Collaborative Neuromuscular Research Group (CINRG).  At present she is a co-chair on the CINRG Publications sub-committee. . She has been an international workshop moderator, regional symposium course director, reviewer for 4 prominent journals, and contributor to book chapters.


Her research constitutes a n unique portfolio. of neurodevelopment, neuro-genetics, and muscular dystrophy. Publications have focused on neurodevelopmental outcomes, natural history, novel genes, and new therapeutics in muscular dystrophyShe has led or actively collaborated on up to 21 ongoing research studies at a time. She has been co-investigator and Principal Investigator (PI) PI and Co-I on several industry, NIH, CDC and MDA sponsored muscular dystrophy, cerebral palsy, and high risk infant studies. She is involved in similar research efforts at VCU where she is PI and Co-I on up to 15 active studies.  . Muscular dystrophy research has included:  translational collaborations, molecular diagnostics, PI for multi-center tissue banking (PI), and site PI CINRG associated clinical trials. She has been involved in CINRG/TRINDS studies since 2012. Her research has contributed to CINRG related manuscripts, and supported the first FDA approvedDMD gene modifying therapy for DMD. She is involved in similar research efforts at VCU, where she is PI and Co-I on 20 studies actively participating in several neuromuscular trials (DMD, Limb Girdle, Myotonic Dystrophy, and SMA), MD STarnet, and translational projects.


Dr. Harper’s clinical and research activities clearly demonstrate her dedicated passion for collaborative scholarship and clinical care in neuromuscular and neurodevelopmental disorders.